Indian biopharmaceutical company Biocon Limited (NSE:BIOCON) is seeking a partner to test generic versions of Novo Nordisk's (CPH:NOVO-B) diabetes drug Ozempic and weight loss treatment Wegovy in China, Reuters reported on Thursday.
An unnamed senior executive told the news agency that Biocon is looking for a Chinese partner for clinical trials on patients in order to sell the drug in China.
Biocon is aiming to launch generic versions of the drugs globally.
Patent protection on semaglutide, a key ingredient in both Ozempic and Wegovy, is due to expire in China in early 2026.
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical
Veeda Group rebrands as 'Veeda Lifesciences'
ANI Pharmaceuticals launches generic Motegrity tablets
Hikma Pharmaceuticals USA receives FDA approval for diabetes drug
Full Circles Therapeutics advances non-viral gene editing innovation